RARE DISEASERESEARCH ATLAS

ORPHA:300319

Charcot-Marie-Tooth disease type 2P

medium confidenceDisorder

Also known as: CMT2P

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

50

45.7th percentile

Trials

0

Interventional, condition-specific

Researchers

330

Distinct authors in sample

Gene link

LRSAM1

Definitive

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

Charcot-Marie-Tooth disease type 2P is a rare, genetic, axonal motor and sensory disorder characterized by adulthood-onset of slowly , occasionally asymmetrical, distal muscle weakness and atrophy (predominantly in the lower limbs), pan-modal sensory loss, muscle cramping in extremities and/or trunk, pes cavus and absent or reduced deep tendon reflexes. Gait anomalies and variable autonomic disturbances, such as erectile dysfunction and urinary urgency, may be associated.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (6)

Charcot-Marie-Tooth disease caused by mutation in LRSAM1 · Charcot-Marie-Tooth disease, axonal, type 2P · Charcot-Marie-Tooth neuropathy, type 2P · Charcot-Marie-Toothe disease, axonal, type 2P · LRSAM1 Charcot-Marie-Tooth disease · autosomal dominant Charcot-Marie-Tooth disease type 2G

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedPresent

    Definitive — LRSAM1

  2. LiteraturePresent

    50 matched papers (33 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 42 for broader category Charcot-Marie-Tooth disease

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (LRSAM1).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

50

50 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

50 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

33 in the last 10 years · medium confidence · 45.7th percentile (publications denominator)

Phrase hits: 50 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

330

Distinct author names in 50 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Christodoulou K3 papers · 2019

    Department of Neurogenetics, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.

    Papers in Europe PMC
  2. 02
    Hu B3 papers · 2022

    Department of Neurology, Center for Human Genetic Research, and Vanderbilt Brain Institute, Vanderbilt University School of Medicine, Nashville, TN.

    Papers in Europe PMC
  3. 03
    Li J3 papers · 2022

    Department of Neurology, Center for Human Genetic Research, and Vanderbilt Brain Institute, Vanderbilt University School of Medicine, Nashville, TN.

    Papers in Europe PMC
  4. 04
    Minaidou A3 papers · 2019

    Department of Neurogenetics, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.

    Papers in Europe PMC
  5. 05
    Nicolaou P3 papers · 2019

    Department of Neurogenetics, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.

    Papers in Europe PMC
  6. 06
    Timmerman V3 papers · 2019

    Peripheral Neuropathy Research Group, University of Antwerp, Antwerp, Belgium vincent.timmerman@uantwerpen.be.

    Papers in Europe PMC
  7. 07
    Baas F2 papers · 2017

    Department of Genome Analysis Academic Medical Center Amsterdam The Netherlands.

    Papers in Europe PMC
  8. 08
    Berciano J2 papers · 2021

    Departments of Neurology, University Hospital, University of Cantabria, and Center for Biomedical Research in the Neurodegenerative Diseases Network, Santander, Spain.

    Papers in Europe PMC
  9. 09
    Burgess RW2 papers · 2015

    The Jackson Laboratory in Bar Harbor, Bar Harbour, ME, 04609, USA.

    Papers in Europe PMC
  10. 10
    Chung KW2 papers · 2020

    Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong Gangnam-Gu, Seoul 135-710, Korea. kwchung@kongju.ac.kr.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial. 42 trials are registered for Charcot-Marie-Tooth disease, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

42 interventional trials matched Charcot-Marie-Tooth disease, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: Charcot-Marie-Tooth disease

42

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Charcot-Marie-Tooth disease type 2P" OR "CMT2P" OR "Charcot-Marie-Tooth disease, axonal, type 2P" OR "Charcot-Marie-Tooth neuropathy, type 2P" OR "Charcot-Marie-Toothe disease, axonal, type 2P" OR "LRSAM1 Charcot-Marie-Tooth disease" OR "autosomal dominant Charcot-Marie-Tooth disease type 2G"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Charcot-Marie-Tooth disease type 2P" OR "CMT2P" OR "Charcot-Marie-Tooth disease, axonal, type 2P" OR "Charcot-Marie-Tooth neuropathy, type 2P" OR "Charcot-Marie-Toothe disease, axonal, type 2P" OR "LRSAM1 Charcot-Marie-Tooth disease" OR "autosomal dominant Charcot-Marie-Tooth disease type 2G" OR "LRSAM1" OR "Charcot-Marie-Tooth disease type 2"

Recall-expansion terms: LRSAM1, Charcot-Marie-Tooth disease type 2

Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"Charcot-Marie-Tooth disease"

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: Charcot-Marie-Tooth disease caused by mutation in LRSAM1

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • "autosomal dominant Charcot-Marie-Tooth disease type 2G" also appears on ORPHA:99941

Ingested 2026-07-27T12:39:14.994Z